KOKatharine Orf

Katharine Orf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katharine Orf has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Base Editing of Hematopoietic Stem Cells Corrects Gain-of-Function Mutations in APDS

    by Katharine Orf, Robert Torrance, Christoph Matti, Nathan White, Leqi Tang, Chunan Liu, Adriana S Albuquerque, Adrian J Thrasher, Sara Benedetti, Klaus Okkenhaug, et al.

    Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS1, APDS2) are rare gain-of-function inborn errors of immunity (IEI) leading to recurrent severe infections, bronchiectasis, lymphoproliferation and lymphoma. APDS1 and APDS2 are caused by mutations in PIK3CD and PIK3R1 respectively, which together encode the subunits of the phosphoinositide 3-kinase  enzyme (PI3K). The only curative therapy is allogeneic hematopoietic stem cell transplantation (alloHSCT), which requires a suitable donor and incurs a significant risk of morbidity and mortality. An adenine base editing strategy was developed to target the most frequent point mutations in APDS1 (p.E1021K, c.3061G>A; ~90% of patients) and APDS2 (c.1425+1G > A; ~50% of patients). Highly efficient correction of the pathogenic point mutation was achieved in patient T cells and hematopoietic stem cells (HSCs) and associated with functional restoration of PI3K signaling, rescue of the activation-induced cell death phenotype and, in APDS2, abrogated expression of the pathogenic splice isoform. Edited HSCs maintained pluripotency and achieved long-term engraftment in immunodeficient mice. A healthy control:APDS1 mixed chimera mouse model suggested that 75% wild-type engraftment generated a wild-type phenotype with respect to T and B cell dysfunction and lymphoproliferation, and thus similar editing efficiencies would be predicted to improve patient clinical phenotype. Together, these data demonstrate successful application of base editing to a gain-of-function IEI, with potential for application in other diseases.

  • Open Access

    Functional restoration of immune defects in STAT1 gain-of-function disease after stem cell gene editing

    by Robert Torrance, Katharine Orf, Nathan White, Christoph Matti, Alexander J. McKenna, Andrea Cosentino, Gabriele Casirati, Adriana S. Albuquerque, Adrian J. Thrasher, Pietro Genovese, et al.

    Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.


  • Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity

    by Katharine Orf, Hannah Al Yousuf, Thomas A. Fox, Nadhira Samsudeen, Suzanne Elcombe, Mari Campbell, Stephen Jolles, Niall Conlon, Charu Chopra, Jennifer M. Tjon, et al.

    Outcomes following international MDT assessment of adult IEI patients for allogeneic HSCT suggest early referral is vital: patients considered too high risk for transplant have poor outcomes with a 3-year overall survival of 31%.

  • Haematopoietic stem cell transplantation in Tanzania

    by Janeth Mtenga, Kate Orf, Jiexin Zheng, Clara Chamba, Harrison Chuwa, Frederick Luoga, Stella W. Malangahe, Per Ole Iversen, Julie Makani


  • Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection

    by Katharine Orf, Srdan Rogosic, Daniel Dexter, Phil Ancliff, Saket Badle, Joe Brierley, Danny Cheng, Caroline Dalton, Garth Dixon, Pascale Du Pré, et al.

    The COVID‐19 pandemic potentially makes treatment of acute leukaemia more difficult. Most induction chemotherapy regimens for acute leukaemia lead to extended periods of cytopaenia and immunosuppression rendering patients vulnerable to opportunistic infections. As with many aspects of SARS‐CoV‐2, there is no universally accepted way of treating patients who present with acute leukaemia and associated infection.